A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52).

Starjemza (ustekinumab-hmny) - Dr. Reddy’s, Bio-Thera Solutions, Pharmapark, Hikma, Biomm, Gedeon Richter, Astra Industrial Group

http://www.ncbi.nlm.nih.gov/pubmed/40784561

Cailing Gu; Katya Zaharieva; Lally Mekokishvili; Min Zheng; Qingfeng Dong; Xiaolei Yang; Xiaoyong Man; Yunhua Deng; Yunpeng Qi

Aug 11, 2025